Advancing T Cell Engagers for Solid Tumors
Philadelphia, PA
Joined May 2018
- Tweets322
- Following571
- Followers494
- Likes97
Pinned Tweet
Context acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody. This is the second clinical-stage T cell engager for solid tumors in our pipeline. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. $CNTX ir.contexttherapeutics.com/n…
Today we announced the first patient has been dosed in the Phase 1 trial of CT-202, our Nectin-4 x CD3 T cell engaging bispecific antibody. Read the full release here: ir.contexttherapeutics.com/n… $CNTX #ImmunoOncology #ClinicalTrials
Today @Context_Tx reported its second quarter 2026 operating and financial results.
Read our full press release here: ir.contexttherapeutics.com/n…
Today, we are pleased to announce positive interim Phase 1 clinical data for our CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer.
To learn more, tune in this morning at 8:00 a.m. ET here: bit.ly/4uzN7xM
📣Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
🗓️Phase 1 initiation for CT-202 trial expected in third quarter of 2026. $CNTX
nasdaq.com/press-release/con…
@Context_Tx announces Q1 2026 earnings
⏰ CTIM-76 Ph1a interim data June 2026
⏰ CT-95 Ph1a interim data Sept 2026
✅ CT-202 Ph1 initiation Q3 2026
💲Expected runway into mid-2027 $CNTX
ir.contexttherapeutics.com/n…
This morning at #AACR26, colleagues from @Context_Tx will present a poster discussion on CT-202, a Nectin‑4 × CD3 T‑cell engager (TCE). Poster link: First in Human Development of CT-202 — Context Therapeutics
This morning at #AACR26, colleagues from @Context_Tx will present a poster discussion on CT-202, a Nectin‑4 × CD3 T‑cell engager (TCE). CT-202 is Context’s 3rd asset to enter clinical development since 2025.
Poster: contexttherapeutics.com/pubs…
Today @Context_Tx reported its full year 2025 operating and financial results. Our lead program, CTIM-76, is on track to present interim Phase 1a data in June 2026.
Read our full press release here: ir.contexttherapeutics.com/n…
🚨Context Therapeutics ($CNTX) highlights CT-95 and CT-202 programs at #SITC2025 Meeting
✅ Both are potentially best-in-class
✅ Conditional activation at the tumor
👍 Complete tumor resolution in mice
👀View here: Publications — Context Therapeutics globenewswire.com/news-relea…
🚨 Context Therapeutics $CNTX Q3 2025 Highlights:
✅ CTIM-76 demonstrates encouraging antitumor activity and safety
✅ CT-95 is approaching target dose levels
💰 $76.9M cash and cash equivalents as of Sept 30, 2025
✅ Expected cash runway into 2027
Context Therapeutics is excited to share that we will be presenting at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting!
#SITC2025 #Immunotherapy #TCE
ir.contexttherapeutics.com/n…
Context Therapeutics $CNTX Q2 2025 Highlights:
✅ CTIM-76 & CT-95 Phase 1 dose-escalation trials ongoing
✅ $83.5M cash and cash equivalents as of June 30, 2025
✅ Expected cash runway into 2027
Read more here: ir.contexttherapeutics.com/n…
#Biotech #Immunotherapy #CancerRes #TCE
$CNTX announces CTIM-76 Trial in Progress poster at #ASCO25
✅Dosing Cohort 3 of Phase 1 trial
✅ CLDN6 x CD3 TCE for ovarian, endometrial & testicular cancers
✅Initial data expected 1H 2026
📍Poster: June 2, Hall A, 1:30 PM CDT
🔗 contexttherapeutics.com/ctim…
#Biotech
We’re excited to welcome Dr. Karen Chagin as Chief Medical Officer at $CNTX, effective June 9, 2025!
With 10+ years leading T cell therapy development at Adaptimmune and Tmunity, she brings deep clinical expertise at a key time for Context.
Read more: tinyurl.com/5c78te9f
🚨 Context Therapeutics $CNTX Q1 2025 Highlights:
✅ CTIM-76 & CT-95 in Phase 1 trials
✅ $89.4M cash and cash equivalents as of March 31, 2025
✅ Expected cash runway into 2027
#Biotech #Immunotherapy #CancerResearch #TCellEngagers
Read more here:ir.contexttherapeutics.com/n…
🚨 We’re excited to welcome Jennifer Dashnau, PhD, MBA as SVP of Technical Operations at Context Therapeutics!
Welcome to the team, Jennifer! 👏
#Biotech #Leadership #Immunotherapy #TCellEngagers #ContextTherapeutics #Oncology #WomenInSTEM
The Context team presented preclinical and translational data for CT-95, our mesothelin-targeting T cell engager, at #AACR2025! View the poster here: contexttherapeutics.com/ct95
#Immunotherapy #Biotech $CNTX
📢 Context Therapeutics CEO Martin Lehr will join the T Cell Engagers panel at #AACR25!
🗓 Thursday, April 24 | 🕠 5:45–6:45 PM CT | 📍 Room W192
Moderated by Leerink Partners, the panel includes leaders from J&J, Zymeworks
#Biotech #Immunotherapy #TCellEngagers
🚀Another big milestone for $CNTX: First patient dosed in Phase 1 clinical trial of CT-95, our mesothelin x CD3 T cell engaging bispecific antibody targeting solid tumors. CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 💡
#Immunotherapy